On May 9, 2025, Guangzhou LBP Medicine Science & Technology Co., Ltd. participated in the 2025 VBEF Future Healthcare and Pharmaceutical Top 100 Conference in Suzhou, engaging in the "Medical AI Large Model Application Innovation Forum." Our Vice General Manager Ms. Cai Xinglun represented LBP, discussing the topic "Breaking the Deadlock—Value Validation, Data Ecosystem, and Payment Mechanism Innovation" with peers from AI enterprises and investment institutions.

Ms. Cai highlighted the global shortage of pathology professionals and LBP's efforts since 2020 to integrate AI into pathology diagnostics. Collaborating with institutions like Peking Union Medical College and Hong Kong University of Science and Technology (Guangzhou), LBP developed AI-assisted cervical cytology diagnostics. These advancements have undergone clinical trials and contributed to expert consensus documents, with findings published in esteemed journals such as Nature Communications, Modern Pathology, and Acta Obstetricia et Gynecologica Scandinavica.

Emphasizing its "Four Modernizations" strategy—standardization, automation, digitization, and intelligence—Anbiping introduced the Xpro 90, China's first fully automated liquid-based cytology intelligent inspection workstation, at the 2024 National Pathology Conference. Currently operational in tertiary hospitals across provinces like Guangdong, Hubei, Hainan, Shanxi, and Zhejiang, the Xpro 90 has been well-received, advancing digital cytology development in these regions.

Looking ahead, Anbiping remains committed to advancing AI integration in pathology, aiming to meet industry demands and promote the digital and intelligent transformation of the field, showcasing China's innovation in pathology+AI on the global stage.